As of June 30, 2025, cash and marketable securities were $101 million as compared to $127 million as of December 31, 2024, providing the Company with an anticipated cash runway into 2027. During the first six months of 2025, $25 million of net cash was used in operating activities.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Drive Buy Rating
- Promising Outlook for Compass Therapeutics: Buy Rating Backed by Tovecimig’s Potential and Strategic Positioning
- Compass Therapeutics resumed with an Outperform at Raymond James
- Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
- Compass Therapeutics Confirms Directors at Annual Meeting